Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

40.65
+2.245.83%
Post-market: 40.10-0.5500-1.35%19:59 EDT
Volume:728.83K
Turnover:29.43M
Market Cap:297.75M
PE:-0.23
High:41.77
Open:38.11
Low:38.06
Close:38.41
Loading ...

Tonix Pharmaceuticals: Net Loss Available to Common Stockholders Was $22.1 Million, or $9.77 per Basic and Diluted Share, for Fourth Quarter 2024

THOMSON REUTERS
·
19 Mar

Tonix Pharmaceuticals: Anticipated Q4 2025 Launch of Tnx-102 Sl for Fibromyalgia

THOMSON REUTERS
·
19 Mar

Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date

THOMSON REUTERS
·
19 Mar

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

GlobeNewswire
·
19 Mar

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
14 Mar

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

GlobeNewswire
·
13 Mar

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

GlobeNewswire
·
11 Mar

BRIEF-Tonix Pharmaceuticals receives MCDC grant for devloping its single-dose Mpox and Smallpox vaccine

Reuters
·
10 Mar

Tonix Pharmaceuticals Announces Grant by Medical Cbrn Defense Consortium (Mcdc) for Development of Tnx-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

THOMSON REUTERS
·
10 Mar

Tonix Pharmaceuticals: Tolerability of Tnx‐801 Vaccination in Immune-Compromised Animal Models Supports Clinical Development

THOMSON REUTERS
·
10 Mar

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

GlobeNewswire
·
10 Mar

Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week

Insider Monkey
·
10 Mar

Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday

Insider Monkey
·
08 Mar

A 41% Surge? This Small-Cap Pharma Stock Just Shook Up the Fibromyalgia Market

GuruFocus.com
·
07 Mar

Tonix Surges 31% Following Positive Phase 3 Fibromyalgia Drug Trial Results

GuruFocus.com
·
07 Mar

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

GlobeNewswire
·
05 Mar

Tonix Pharmaceuticals presents new data on TNX-102 SL treatment

TIPRANKS
·
04 Mar

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

GlobeNewswire
·
04 Mar

TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…

Zacks Small Cap Research
·
24 Feb

Tonix Pharmaceuticals Rises After Preliminary 2024 Results

MT Newswires Live
·
08 Feb